Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Time to Sell?

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) hit a new 52-week low during trading on Tuesday . The company traded as low as $19.60 and last traded at $19.71, with a volume of 41866 shares changing hands. The stock had previously closed at $20.16.

Analyst Ratings Changes

Several equities research analysts have recently commented on GPCR shares. JMP Securities restated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective on the stock. William Blair started coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Trading Down 3.5 %

The business’s 50 day simple moving average is $25.85 and its 200 day simple moving average is $32.87. The firm has a market capitalization of $1.11 billion, a PE ratio of -26.30 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. Analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Assetmark Inc. raised its position in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Structure Therapeutics during the third quarter worth $1,337,000. Dearborn Partners LLC purchased a new stake in shares of Structure Therapeutics during the third quarter valued at $202,000. Natixis Advisors LLC increased its stake in Structure Therapeutics by 40.4% in the 3rd quarter. Natixis Advisors LLC now owns 26,675 shares of the company’s stock worth $1,171,000 after buying an additional 7,670 shares during the period. Finally, Bank of Montreal Can boosted its position in Structure Therapeutics by 71.6% in the 3rd quarter. Bank of Montreal Can now owns 46,502 shares of the company’s stock valued at $1,941,000 after buying an additional 19,408 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.